Advances in Nanotechnology for Lymphoma Treatment: Targeted Delivery, Immunomodulation, and TME-Responsive Therapy Strategies - PubMed
5 hours ago
- #immunotherapy
- #nanotechnology
- #lymphoma
- Lymphoma is a heterogeneous malignant proliferative disease of lymphocytes, exhibiting characteristics of both liquid and solid tumors.
- Current treatments like targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T therapy have transformed lymphoma treatment but face limitations such as short plasma circulation time, low bioavailability, drug resistance, and dose-dependent toxicity.
- Nanotechnology offers targeted delivery systems that enable tumor-specific targeting, reducing off-target toxicity.
- Nano-immunotherapeutic systems, including nanobody-based CAR-T therapy and mRNA-LNP nanovaccines, address issues like drug resistance and relapse caused by antigen escape, promoting long-term anti-tumor immunity.
- Smart designs responsive to the tumor microenvironment (TME) enhance drug accumulation and release efficiency at the lesion site.
- Innovative nanotech-based therapies are moving from the lab to the clinic, integrating multiple therapeutic modalities (e.g., chemodynamic therapy, immunomodulation, gene silencing) for synergistic effects.
- These advancements provide new paradigms for lymphoma treatment by improving efficacy and reducing toxicity.